PEI800-EpoxyC8-22 Lipid Nanocomplexes for Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polyethyleneimine (PEI)-based nanodelivery systems for gene therapy face challenges with low transfection efficacy and high toxicity due to high cationic density, necessitating improved compositions and methods for efficient and safe delivery of nucleic acids into cells.
Innovation Solution
The development of transfection complexes using PEI800-EpoxyC8-22 lipids complexed with nucleic acids on nanoparticles, which are synthesized at specific molar ratios and formed into core-shell nanoparticles or liposomes, utilizing biodegradable polymers like PLGA to enhance biocompatibility and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high molecular weight PEI is used to enhance transfection efficacy, then gene delivery efficiency is improved, but cytotoxicity increases
Solution Approach 1:
The patent changes the molecular weight parameter of PEI from high molecular weight (25 kDa) to low molecular weight (800 Da), which fundamentally alters the balance between transfection efficacy and cytotoxicity. The low molecular weight PEI maintains sufficient cationic charge for DNA binding while eliminating the excessive cytotoxicity associated with high molecular weight PEI
Solution Approach 2:
The patent creates a composite nanocomplex system combining low molecular weight PEI with biodegradable polymers (such as poly(lactic-co-glycolic acid) PLGA) and lipid components. This composite structure enables the PEI to function as a DNA binding agent while the biodegradable polymer matrix provides structural support and controlled degradation, reducing overall cytotoxicity
2Productivity
If high cationic density PEI is used to condense pDNA, then gene delivery is improved, but toxicity increases due to lack of backbone biodegradability
Solution Approach 1:
The patent modifies the chemical structure of PEI by changing the backbone composition to include biodegradable units while maintaining the cationic amine groups necessary for DNA condensation. This structural parameter change allows the PEI derivative to perform its gene delivery function and then degrade into non-toxic fragments
Solution Approach 2:
The patent employs low molecular weight PEI (800 Da) which has a short half-life in the cellular environment compared to high molecular weight PEI. The low molecular weight PEI performs its DNA binding and delivery function rapidly, then degrades quickly, avoiding the long-term accumulation and chronic toxicity associated with high molecular weight PEI
3Object-affected harmful factors
If low molecular weight PEI is used to reduce cytotoxicity, then toxicity is reduced, but transfection efficacy decreases
Solution Approach 1:
The patent combines low molecular weight PEI with biodegradable polymer nanoparticles (such as PLGA nanoparticles) to create a composite delivery system. The low molecular weight PEI provides sufficient cationic charge for DNA binding while the nanoparticle carrier enhances cellular uptake and protects the PEI-DNA complex, compensating for the reduced efficacy that would result from using low molecular weight PEI alone
Data Source
AI summary
The present invention includes synthesis of polyethyleneimine800-EpoxyC8-22 (PEI800-C8-22) lipids, e.g., Polyethyleneimine800-EpoxyC16 (PEI800-C16), PEI12C16, PEI8C16, and PEI4C16 lipids, compositions and methods for transfecting primary leukocytes, myeloid cells, lymphoid cells, monocytes, macrophages and dendritic cells (DC) comprising a transfection complex comprising: one or more nanoparticles; and Polyethyleneimine800-EpoxyC16 (PEI800-C16), PEI12C16, PEI8C16, and PEI4C16 lipids complexed with one or more nucleic acids, such as, e.g., DNA, RNA, nucleic acid vectors, shRNA, miRNA, and RNAi on or about the nanoparticles.